Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iPLTs-01
- Development stage
- Preclinical
- Lead developer
- HemaCell Biotechnology
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
iPLTs-01 is an induced pluripotent stem cell (iPSC)-derived platelet cell therapy being developed by HemaCell Therapeutics (Xue Ji Bio) for the treatment of thrombocytopenia. The therapy utilizes stem cell reprogramming and differentiation technologies to produce functional platelets in vitro from iPSCs. These manufactured platelets are intended to be administered to patients to replace or augment platelet function, addressing low platelet counts without the reliance on donor-derived blood products. iPLTs-01 is currently in the preclinical stage of development and is part of a pipeline that includes various blood type-specific and engineered platelet products.
- Other names
- iPLTs-01 (A-type)iPSC-derived platelet product
Beyond the preview
Go deeper on iPLTs-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iPLTs-01.